Budesonide + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proctitis
Conditions
Proctitis, Proctosigmoiditis
Trial Timeline
Nov 20, 2009 → Mar 18, 2013
NCT ID
NCT01008423About Budesonide + Placebo
Budesonide + Placebo is a phase 3 stage product being developed by Bausch Health for Proctitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01008423. Target conditions include Proctitis, Proctosigmoiditis.
What happened to similar drugs?
0 of 3 similar drugs in Proctitis were approved
Approved (0) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01008423 | Phase 3 | Completed |
| NCT01008410 | Phase 3 | Completed |
Competing Products
3 competing products in Proctitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mesalamine + Canasa + Placebo | Sandoz Group | Phase 3 | 29 |
| Budesonide Foam | Bausch Health | Phase 3 | 26 |
| Budesonide + Placebo | Bausch Health | Phase 3 | 34 |